H.C. Wainwright analyst Swayampakula Ramakanth notes that Immunogen reported strong top-line results from the Phase 3 MIRASOL study in patients with folate receptor alpha-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy. The firm believes the "robust" data set from MIRASOL paves a smooth path to a full approval for Elahere. H.C. Wainwright believes Elahere’s superiority to chemotherapy demonstrated in MIRASOL further reinforces the therapeutic potential of the drug in patients with FRalpha-positive ovarian cancer. Given that, it expects Elahere to be increasingly used in off-label patient populations, such as platinum-sensitive as well as earlier lines of ovarian cancer patients with FRalpha expression. H.C. Wainwright reiterates a Buy rating on the shares with a price target of $15.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMGN:
- ImmunoGen Skyrockets after Positive Topline Data
- ImmunoGen’s MIRASOL trial results represent best-case scenario, says Guggenheim
- ImmunoGen reports ‘positive’ results from Phase 3 MIRASOL trial
- ImmunoGen Rockets Up on Great Sales, Earnings
- ImmunoGen raises FY23 revenue excluding ELAHERE view to $45M-$50M